Skip to main content

General Practice 

Often the first point of contact for patients seeking care, general practice clinicians can be life-long partners in their patients’ health. Syndromic infectious disease testing gives general practitioners the tools to make timely, informed treatment decisions while giving patients the answers they seek.

Primary Care Infectious Disease Testing

Patients often turn to general practice clinics when they are suffering from common respiratory or gastrointestinal infections. But diagnosing these infections based on symptoms alone is difficult, if not impossible. Onsite infectious disease diagnostics are convenient for patients and help avoid the expense of offsite or send-out testing—all while giving clinicians the fast, comprehensive results they need to make appropriate and targeted treatment decisions. 


For results that are fast and accurate, the BIOFIRE TORCH uses PCR technology to simultaneously test for a comprehensive grouping of targets in about an hour. For use in CLIA-moderate settings.

BIOFIRE® FILMARRAY® 2.0 EZ Configuration

The BIOFIRE 2.0 EZ facilitates fast, onsite respiratory testing. Designed to be used with the BIOFIRE RP2.1-EZ Panel (EUA) in CLIA-waived settings, the system offers results in ~45 minutes.

BIOFIRE® Respiratory 2.1 Panel

Identify 22 of the most common viral and bacterial respiratory pathogens, including SARS-CoV-2, influenza A and B viruses, RSV, and many others. All in one test, with results in about 45 minutes. Onsite in CLIA-moderate settings.

BIOFIRE® Respiratory 2.1-EZ Panel (EUA)*

Perform in-clinic testing of those suspected of COVID-19. This syndromic panel identifies 19 probable bacterial and viral respiratory targets in one fast and easy test. *Authorized for emergency use only. 

BIOFIRE® FILMARRAY® Gastrointestinal Panel

Test for 22 gastrointestinal pathogens, including bacteria, yeast, and parasites, in one easy-to-perform test—with results in about an hour. Onsite in CLIA-moderate settings.

BIOFIRE® Joint Infection Panel

Overcome the challenges of traditional joint infection testing with a syndromic panel that identifies 31 pathogenic targets and 8 antimicrobial resistance genes—all onsite in CLIA-moderate settings.